TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
2.1 MARKETS COVERED 81
2.2 GEOGRAPHICAL SCOPE 82
2.3 YEARS CONSIDERED FOR THE STUDY 83
2.4 CURRENCY AND PRICING 83
2.5 DBMR TRIPOD DATA VALIDATION MODEL 84
2.6 MULTIVARIATE MODELLING 87
2.7 PRODUCTS & SERVICES LIFELINE CURVE 87
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 88
2.9 DBMR MARKET POSITION GRID 89
2.10 MARKET TESTING TYPE COVERAGE GRID 91
2.11 VENDOR SHARE ANALYSIS 92
2.12 SECONDARY SOURCES 93
2.13 ASSUMPTIONS 93
3 EXECUTIVE SUMMARY 94
4 PREMIUM INSIGHTS 97
4.1 PESTEL ANALYSIS 98
4.2 PORTERS FIVE FORCES 99
4.3 PATENT ANALYSIS 100
5 INDUSTRIAL INSIGHTS 103
5.1 KEY PRICING STRATEGY 103
6 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, REGULATIONS 105
7 MARKET OVERVIEW 108
7.1 DRIVERS 110
7.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 110
7.1.2 GROWING NUMBER OF CASES OF DYSLIPIDEMIA 111
7.1.3 RAPID CHANGES IN LIFESTYLE CHANGES LEAD TO LIPID DISORDERS 112
7.1.4 RISE IN PREFERENCE FOR HOMECARE TESTING IN LIPID PANEL TESTING 113
7.2 RESTRAINTS 114
7.2.1 STRICT GOVERNMENT REGULATIONS 114
7.2.2 HIGH COST ASSOCIATED WITH TESTING PANELS 115
7.3 OPPORTUNITIES 116
7.3.1 GROWTH IN TECHNOLOGICAL ADVANCEMENTS 116
7.3.2 RISE IN THE PREVALENCE OF OBESITY AMONG PEOPLE 116
7.3.3 INCREASING ADOPTION OF POINT-OF-CARE LIPID PANEL TESTING 117
7.4 CHALLENGES 118
7.4.1 LACK OF SKILLED & CERTIFIED PROFESSIONALS 118
7.4.2 LACK OF STANDARDIZATION OF LIPID PANEL TESTING 118
8 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY PRODUCTS & SERVICES 120
8.1 OVERVIEW 121
8.2 SERVICES 124
8.2.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 125
8.2.2 TOTAL CHOLESTEROL TEST 125
8.2.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 125
8.2.4 TRIGLYCERIDES/ VLDL TEST 126
8.2.5 NON-HDL CHOLESTEROL TEST 126
8.2.6 OTHERS 127
8.3 KITS 127
8.3.1 STRIPS 128
8.3.1.1 THREE-ANALYTE TEST STRIPS 128
8.3.1.2 DUAL-ANALYTE TEST STRIPS 128
8.3.1.3 SINGLE-ANALYTE TEST STRIPS 128
8.3.2 LANCETS 128
8.3.3 CONTROLS 129
8.3.3.1 MULTI-CHEMISTRY CONTROLS 129
8.3.3.2 HDL CHOLESTEROL CONTROLS 129
8.3.3.3 OTHERS 129
8.3.4 CAPILLARY TUBES 129
8.4 DEVICES 130
8.4.1 BY MODALITY 130
8.4.1.1 STANDALONE 131
8.4.1.2 HANDHELD 131
8.4.1.3 PORTABLE 131
8.4.2 BY TYPE 131
8.4.2.1 LABORATORY BASED 131
8.4.2.2 POINT OF CARE BASED 131
9 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY PRESCRIPTION MODE 132
9.1 OVERVIEW 133
9.2 PRESCRIPTION-BASED TESTING 136
9.3 OTC-BASED TESTING 137
10 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY APPLICATION 138
10.1 OVERVIEW 139
10.2 HYPERLIPIDEMIA 142
10.2.1 TOTAL CHOLESTEROL TEST 143
10.2.2 TRIGLYCERIDES/ VLDL TEST 143
10.2.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 143
10.2.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 143
10.2.5 NON-HDL CHOLESTEROL TEST 143
10.2.6 OTHERS 143
10.3 HYPERTRIGLYCERIDEMIA 144
10.3.1 TRIGLYCERIDES/ VLDL TEST 145
10.3.2 TOTAL CHOLESTEROL TEST 145
10.3.3 LOW DENSITY LIPOPROTEIN (LDL) TEST 145
10.3.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 145
10.3.5 NON-HDL CHOLESTEROL TEST 145
10.3.6 OTHERS 145
10.4 ATHEROSCLEROSIS 146
10.4.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 147
10.4.2 TOTAL CHOLESTEROL TEST 147
10.4.3 TRIGLYCERIDES/ VLDL TEST 147
10.4.4 HIGH DENSITY LIPOPROTEIN (HDL) TEST 147
10.4.5 NON-HDL CHOLESTEROL TEST 147
10.4.6 OTHERS 147
10.5 FAMILIAL HYPERCHOLESTEROLEMIA 148
10.5.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 149
10.5.2 TOTAL CHOLESTEROL TEST 149
10.5.3 HIGH DENSITY LIPOPROTEIN (HDL) TEST 149
10.5.4 TRIGLYCERIDES/ VLDL TEST 149
10.5.5 NON-HDL CHOLESTEROL TEST 149
10.5.6 OTHERS 149
10.6 HYPO LIPOPROTEINEMIA 150
10.6.1 LOW DENSITY LIPOPROTEIN (LDL) TEST 151
10.6.2 HIGH DENSITY LIPOPROTEIN (HDL) TEST 151
10.6.3 TRIGLYCERIDES/ VLDL TEST 151
10.6.4 TOTAL CHOLESTEROL TEST 151
10.6.5 NON-HDL CHOLESTEROL TEST 151
10.6.6 OTHERS 151
10.7 TANGIER DISEASE 152
10.7.1 HIGH DENSITY LIPOPROTEIN (HDL) TEST 153
10.7.2 LOW DENSITY LIPOPROTEIN (LDL) TEST 153
10.7.3 TOTAL CHOLESTEROL TEST 153
10.7.4 TRIGLYCERIDES/ VLDL TEST 153
10.7.5 NON-HDL CHOLESTEROL TEST 153
10.7.6 OTHERS 153
10.8 OTHERS 154
11 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY END USER 155
11.1 OVERVIEW 156
11.2 HOSPITAL 159
11.2.1 BY TYPE 159
11.2.1.1 PRIVATE 160
11.2.1.1.1 SERVICES 160
11.2.1.1.2 KITS 160
11.2.1.1.3 DEVICES 160
11.2.1.2 PUBLIC 160
11.2.1.2.1 SERVICES 161
11.2.1.2.2 KITS 161
11.2.1.2.3 DEVICES 161
11.2.2 BY TIER 161
11.2.2.1 TIER 1 161
11.2.2.1.1 SERVICES 162
11.2.2.1.2 KITS 162
11.2.2.1.3 DEVICES 162
11.2.2.2 TIER 2 162
11.2.2.2.1 SERVICES 162
11.2.2.2.2 KITS 162
11.2.2.2.3 DEVICES 162
11.2.2.3 TIER 3 162
11.2.2.3.1 SERVICES 163
11.2.2.3.2 KITS 163
11.2.2.3.3 DEVICES 163
11.3 DIAGNOSTIC CLINICS 163
11.3.1 SERVICES 164
11.3.2 KITS 164
11.3.3 DEVICES 164
11.4 SPECIALTY CLINICS & PHYSICIAN OFFICES 165
11.4.1 SERVICES 166
11.4.2 KITS 166
11.4.3 DEVICES 166
11.5 REFERENCE LABORATORIES 166
11.5.1 SERVICES 167
11.5.2 KITS 167
11.5.3 DEVICES 167
11.6 AMBULATORY SURGICAL CENTERS 167
11.6.1 SERVICES 168
11.6.2 KITS 168
11.6.3 DEVICES 168
11.7 PATHOLOGY LABORATORIES 169
11.7.1 SERVICES 170
11.7.2 KITS 170
11.7.3 DEVICES 170
11.8 ACADEMIC AND RESEARCH INSTITUTES 170
11.8.1 SERVICES 171
11.8.2 KITS 171
11.8.3 DEVICES 171
11.9 OTHERS 172
12 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY DISTRIBUTION CHANNEL 173
12.1 OVERVIEW 174
12.2 DIRECT TENDER 177
12.3 RETAIL PHARMACY 177
12.3.1 HOSPITAL PHARMACIES 178
12.3.2 DRUG STORES 178
12.3.3 OTHERS 178
12.4 ONLINE SALES 179
12.5 OTHERS 180
13 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, BY REGION 181
13.1 MIDDLE EAST AND AFRICA 182
13.1.1 SOUTH AFRICA 199
13.1.2 SAUDI ARABIA 212
13.1.3 EGYPT 225
13.1.4 UAE 238
13.1.5 ISRAEL 251
13.1.6 REST OF MIDDLE EAST AND AFRICA 264
14 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, COMPANY LANDSCAPE 265
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 265
15 SWOT ANALYSIS 266
16 MIDDLE EAST & AFRICA LIPID PANEL TESTING MARKET, COMPANY PROFILE 267
16.1 QUEST DIAGNOSTICS INCORPORATED 267
16.1.1 COMPANY SNAPSHOT 267
16.1.2 REVENUE ANALYSIS 268
16.1.3 COMPANY SHARE ANALYSIS 268
16.1.4 PRODUCT PORTFOLIO 269
16.1.5 RECENT DEVELOPMENTS 269
16.2 EUROFINS SCIENTIFIC 270
16.2.1 COMPANY SNAPSHOT 270
16.2.2 REVENUE ANALYSIS 270
16.2.3 COMPANY SHARE ANALYSIS 271
16.2.4 PRODUCT PORTFOLIO 271
16.2.5 RECENT DEVELOPMENT 271
16.3 LABORATORY CORPORATION OF AMERICA HOLDINGS 272
16.3.1 COMPANY SNAPSHOT 272
16.3.2 REVENUE ANALYSIS 272
16.3.3 COMPANY SHARE ANALYSIS 273
16.3.4 PRODUCT PORTFOLIO 273
16.3.5 RECENT DEVELOPMENT 274
16.4 F. HOFFMANN-LA ROCHE LTD. 275
16.4.1 COMPANY SNAPSHOT 275
16.4.2 REVENUE ANALYSIS 275
16.4.3 COMPANY SHARE ANALYSIS 276
16.4.4 PRODUCT PORTFOLIO 276
16.4.5 RECENT DEVELOPMENT 276
16.5 RANDOX LABORATORIES LTD. 277
16.5.1 COMPANY SNAPSHOT 277
16.5.2 COMPANY SHARE ANALYSIS 277
16.5.3 PRODUCT PORTFOLIO 278
16.5.4 RECENT DEVELOPMENT 278
16.6 ABBOTT 279
16.6.1 COMPANY SNAPSHOT 279
16.6.2 REVENUE ANALYSIS 279
16.6.3 COMPANY SHARE ANALYSIS 280
16.6.4 PRODUCT PORTFOLIO 280
16.6.5 RECENT DEVELOPMENT 281
16.7 AWARENESS TECHNOLOGY, INC. 282
16.7.1 COMPANY SNAPSHOT 282
16.7.2 PRODUCT PORTFOLIO 282
16.7.3 RECENT DEVELOPMENTS 282
16.8 ARUP LABORATORIES 283
16.8.1 COMPANY SNAPSHOT 283
16.8.2 PRODUCT PORTFOLIO 283
16.8.3 RECENT DEVELOPMENT 283
16.9 BIO-RAD LABORATORIES, INC. 284
16.9.1 COMPANY SNAPSHOT 284
16.9.2 REVENUE ANALYSIS 284
16.9.3 PRODUCT PORTFOLIO 285
16.9.4 RECENT DEVELOPMENT 285
16.10 BECKMAN COULTER, INC. (SUBSIDIARY OF DANAHER) 286
16.10.1 COMPANY SNAPSHOT 286
16.10.2 REVENUE ANALYSIS 286
16.10.3 PRODUCT PORTFOLIO 287
16.10.4 RECENT DEVELOPMENT 287
16.11 BOSTON HEART DIAGNOSTICS CORPORATION 288
16.11.1 COMPANY SNAPSHOT 288
16.11.2 PRODUCT PORTFOLIO 288
16.11.3 RECENT DEVELOPMENT 289
16.12 CPC DIAGNOSTICS 290
16.12.1 COMPANY SNAPSHOT 290
16.12.2 PRODUCT PORTFOLIO 290
16.12.3 RECENT DEVELOPMENT 290

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.